We’re excited to announce that bwtech client, Previse, has signed a definitive agreement to be acquired by Castle Biosciences (Nasdaq: CSTL), a diagnostics company known for developing innovative tests that guide patient care. This exciting partnership marks a new chapter for the Previse team, expanding their ability to impact lives through the early detection of GI diseases.
Founded in 2018, Previse has been focused on saving lives through earlier, more accurate diagnosis of esophageal cancer and other chronic acid reflux–related conditions. Their flagship test, Esopredict®, is based on methylation technology developed by Dr. Stephen Meltzer and the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine. This science, backed by NIH support and years of research, forms the core of our mission: to catch disease before it progresses.
By joining Castle Biosciences, Previse gains a powerful partner with a strong presence in gastroenterology, including the TissueCypher® Barrett’s Esophagus test. Together, the organizations’ technologies and shared vision will help physicians better predict and prevent progression to esophageal cancer, ultimately improving outcomes for more patients.
“We are excited about joining Castle,” said Daniel Lunz, chief executive officer of Previse. “We look forward to the advancements in care we can make together for patients with GI diseases – our technologies, combined with Castle’s TissueCypher test and history of executional success.”
The acquisition is expected to close in the coming weeks, pending customary closing conditions.
Please join us in congratulating Previse on this exciting milestone!